Publications by authors named "Hongshuang Wan"

Article Synopsis
  • Researchers have developed a new strategy for breast cancer treatment that combines immunotherapy, chemotherapy, and photodynamic therapy (PDT) using a targeted nanoplatform.
  • This nanoplatform uses liposomes to deliver hypoxia-sensitive drugs like tirapazamine (TPZ) and a PD-L1 inhibitor (BMS-202) to enhance cancer cell death.
  • Studies have shown that this approach effectively reduces tumor growth and metastasis, offering a promising method for better breast cancer therapies.
View Article and Find Full Text PDF

We have developed an ovarian cancer-targeted drug delivery system based on a follicle-stimulating hormone receptor (FSHR) peptide. The lipophilic chemotherapeutic drug SN38 and the photosensitizer IR820 were loaded into the phospholipid bilayer of liposomes. The combination of chemotherapy and phototherapy has become a promising strategy to improve the therapeutic effect of chemotherapy drugs on solid tumors.

View Article and Find Full Text PDF

A keloid is a benign tumor manifested as abnormal fibroplasia on the surface of the skin. Curing keloids has become a major clinical challenge, and searching for new treatments and medications has become critical. In this study, we developed a LA67 liposome-loaded thermo-sensitive hydrogel (LA67-RL-Gel) with active targeting for treating keloids via peritumoral injection and explored the anti-keloid mechanism.

View Article and Find Full Text PDF

Epigallocatechin gallate (EGCG) has attracted the increasing attention of many researchers, especially in the field of tumor therapy. However, EGCG has poor fat solubility, low stability, low bioavailability, and a high effective dose in vivo. Traditional drug delivery methods are difficult to deliver the water-soluble EGCG efficiently and in high doses to tumor sites.

View Article and Find Full Text PDF

Introduction: The blood-brain barrier (BBB) is a key obstacle to the delivery of drugs into the brain. Therefore, it is essential to develop an advanced drug delivery nanoplatform to solve this problem. We previously screened a small rabies virus glycoprotein 15 (RVG) peptide with 15 amino acids and observed that most of the RVG-modified nanoparticles entered the brain within 1 h of administration.

View Article and Find Full Text PDF